Ruxolitinib phosphate is under clinical development by Incyte and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome.

INR:3550. the daily life of the immortal king season 5 release date Breaking news! Chinese scientists reveal the mechani ...

Using real-world data, Song found that patients treated with CAR T-cell therapies had improved overall survival compared with ...

The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the ...

A recent review published in eGastroenterology discusses recent advancements in understanding alcohol-associated liver ...

Blinatumomab in addition to standard chemotherapy improved pediatric patients with NCI standard-risk B-cell acute lymphoblastic leukemia survival outcomes.

The following is a summary of “REmoval of cytokines during CArdiac surgery (RECCAS): a randomised controlled trial,” published in the December 2024 issue of Critical Care by Hohn et al.

Cytokine release syndrome (CRS) developed in all patients, including grade 3/4 events in nearly half. "Bicistronic CD19/CD22-targeted CAR T-cell therapy is a safe and effective regimen which ...

Six CAR-T-cell therapies have been approved by the European Commission and the US FDA, and other T-cell therapies are being ...

The first patient was enrolled in a phase 3 trial for patients with non-metastatic uveal melanoma to either receive Kimmtrak ...

T-cell therapy is a type of cancer immunotherapy where patients' T-cells are collected and genetically modified to produce ...